Metabolic

Latest News

Tool Developed to Assess Long-Term CVD Risk, Benefit of Lipid-Lowering Intervention

The blood levels of non-high density lipoprotein cholesterol were found to have a strong association with the long-term risk for a cardiovascular disease event.

Diabetes Mellitus May Increase Risk for Developing Heart Failure

Increased risk for heart failure also seen in group of participants without diastolic dysfunction

High Lipoprotein(a) Is Risk Factor for CVD in Type 1 Diabetes

Lp(a) is a significant risk factor for macrovascular disease, albuminuria, and calcified aortic valve disease for patients with type 1 diabetes.

Poor Diet Contributes Substantially to Cardiometabolic Disease Costs

Suboptimal diet accounts for 18.2 percent of all cardiometabolic disease costs in the United States.

Examining the Associations Between Oral Nitrate-Reducing Bacteria and Cardiometabolic Outcomes

A greater quantity of oral nitrate-reducing bacteria was found to be associated with reduced plasma glucose and insulin resistance in young to middle-aged adults.

ADA 2020 Standards of Care Incorporate CVD Risk Stratification, New Medications

The American Diabetes Association (ADA) has published an update to their Standards of Medical Care in Diabetes for 2020.

First-Episode Psychosis May Be a Key Intervention Point for Cardiometabolic Risk

Adverse cardiometabolic outcomes were more commonly observed among patients from black and ethnic minority groups compared with white patients.

Impact of Changes in Metabolic Syndrome Status on Risk for Major Adverse Cardiovascular Events

Associations were established between recovery from and development of metabolic syndrome and reduced and elevated risk for major adverse cardiovascular events, respectively.

Racial Differences Seen With Hypertrophic Cardiomyopathy

Racial differences in disease expression and adverse clinical outcomes exist between black and white patients with hypertrophic cardiomyopathy.

Addition of Evolocumab to Statin Therapy May Reduce LDL-C in Patients With ACS

In patients with acute coronary syndrome, the early in-hospital addition of evolocumab to high-dose statin therapy was found to be safe, well tolerated, and efficacious in reducing low-density lipoprotein cholesterol levels.